{"nctId":"NCT02483078","briefTitle":"Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140","startDateStruct":{"date":"2015-10","type":"ACTUAL"},"conditions":["HIV"],"count":52,"armGroups":[{"label":"PRO 140","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: PRO 140","Drug: Optimized Background Regimen"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Optimized Background Regimen"]}],"interventions":[{"name":"PRO 140","otherNames":["PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5"]},{"name":"Placebo","otherNames":[]},{"name":"Optimized Background Regimen","otherNames":["Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history."]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and females, age ≥ 18 years\n2. Exclusive CCR5-tropic virus at Screening Visit\n3. Have a history of at least 3 months on current antiretroviral regimen\n4. Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within three drug classes\n\n   OR\n\n   Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within two drug classes and have limited treatment options. The options may be limited as a result of drug antiretroviral class cross-resistance or documented treatment intolerance.\n5. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure.\n6. Plasma HIV-1 RNA ≥ 400 copies/mL at Screening Visit and documented detectable viral load (HIV-1 RNA \\>50 copies/ml) within the last 3 months prior to Screening Visit.\n7. Laboratory values at Screening of:\n\n   * Absolute neutrophil count (ANC) ≥ 750/mm3\n   * Hemoglobin (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)\n   * Platelets ≥ 75,000 /mm3\n   * Serum alanine transaminase (SGPT/ALT) \\< 5 x upper limit of normal (ULN)\n   * Serum aspartate transaminase (SGOT/AST) \\< 5 x ULN\n   * Bilirubin (total) \\< 2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease\n   * Creatinine ≤ 1.5 x ULN\n8. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator\n9. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives \\[male condom, female condom, or diaphragm with a spermicidal gel\\], hormonal contraceptives \\[implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings\\], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.\n10. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.\n\nNote: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.\n\nExclusion Criteria:\n\n1. Documented CXCR4-tropic virus or Dual/Mixed tropic (R5X4) virus\n2. Patients with no viable treatment options (≤ 1 fully active drug)\n3. Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma) Note: Subjects infected by the hepatitis B virus or early stage hepatitis C virus will be eligible for the study.\n4. Laboratory test values of ≥ grade 3 DAIDS laboratory abnormality with the exception of the absolute CD4+ count criterion of \\< 200/mm3\n5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study\n6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose\n7. Any vaccination within 2 weeks prior to the first study dose.\n8. Subjects weighing \\< 35kg\n9. History of anaphylaxis\n10. History of Bleeding Disorder or patients on anti-coagulant therapy\n11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit or during the study\n12. Any known allergy or antibodies to the study drug or excipients\n13. Treatment with any of the following:\n\n    * Radiation or cytotoxic chemotherapy with 30 days prior to the Screening Visit or during the study\n    * Immunosuppressants within 60 days prior to the Screening Visit or during the study\n    * Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the Screening Visit or during the study\n    * Oral or parenteral corticosteroids within 30 days prior to the Screening Visit or during the study. Subjects on chronic steroid therapy \\> 5 mg/day will be excluded with the following exception:\n\n      * Subjects on inhaled, nasal, or topical steroids will not be excluded.\n14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period","description":"The primary efficacy endpoint will be proportion of participants with a 0.5 log10 or greater reduction in HIV-1 RNA viral load from baseline at the end of the one week double-blind treatment period (Part 1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".64","spread":null},{"groupId":"OG001","value":".23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".36","spread":null},{"groupId":"OG001","value":".77","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option.","description":"Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group:\n\na. resistance to ART drugs within two drug class with limited treatment option (N = 24).\n\nThis outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period .\n\nThe total number of participants in the study ITT population, 52, is further stratified into two subgroups:\n\n1. Participants with resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24)\n2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28)\n\nThis measure includes only the 24 participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Options","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".7273","spread":null},{"groupId":"OG001","value":".2308","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes","description":"Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group:\n\na. Resistance to ART drugs within three drug classes (N = 28)\n\nThis outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period .\n\nThe total number of participants in the study ITT population, 52, is further stratified into two subgroups as follows:\n\n1. Participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24)\n2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28)\n\nThis measure includes only the 28 participants with resistance to ART drugs within three drug classes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".5714","spread":null},{"groupId":"OG001","value":".2308","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum","description":"The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded. The change from baseline in HIV-1 RNA levels was to be compared between the two (2) groups using Analysis of covariance (ANCOVA) with the stratification factor (i.e., Resistance to ART drugs at the time of randomization) included in the model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.45"},{"groupId":"OG001","value":"0.1","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25 for All Patients and Within Each Stratum","description":"The number and percentages of subjects achieving HIV-1 RNA \\< 400 copies/mL at Week 25, from the open label portion of the study, are presented","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage and Number of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25 for All Patients and Within Each Stratum","description":"The number and percentages of subjects achieving HIV-1 RNA \\< 50 copies/mL at Week 25 are presented. This is from the 24 week open label portion of the of the trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum","description":"The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum","description":"The raw and change from baseline in CD4 cell count at the end of the 1-week double blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":"154"},{"groupId":"OG001","value":"25","spread":"131"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum","description":"The raw and change from baseline in CD4 cell count at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.9","spread":"175.2"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum","description":"The number and percentage of subjects with a ≥ 1log10 or greater reduction in HIV-1 RNA viral load from baseline was to be presented for the two (2) treatment groups. The analysis of change in viral load was done for subjects with ≥ 1.0 log10 reduction in HIV-1 RNA after the first week of treatment. The analysis is presented for the ITT population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":null},{"groupId":"OG001","value":".0385","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions","description":"Assessments of subject-perceived injection site pain using the Pain Visual Analog Scale (VAS) were performed during each visit to the clinic for a study visit.\n\nBeginning at Treatment Visit 2 (T2), subjects were asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, \"no pain\" on the left side and \"pain as bad as it could possibly be\" on the right side of the line. The subject marks on the line or by pointing to a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks\n\nThe scale range is 0mm to 100 mm, with 0 mm = No Pain and 100 mm = Pain as bad as it could possibly be.\n\nIn this measurement, a lower number corresponds to less perceived pain.\n\nT# = Visit Week#","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"8.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"7.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".7","spread":"4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".8","spread":"4.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".4","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":"1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".9","spread":"3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".8","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".4","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".4","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".4","spread":"1.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":"1.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":"1.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".8","spread":"4.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".4","spread":"1.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".3","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":".9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".2","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":".2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":".1","spread":".6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":".3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale","description":"The investigator was to carefully evaluate the comments of each subject and the response to treatment in order to judge the true nature and severity of the AE. The question of the relationship of AEs to study drug should have been determined by the investigator after thorough consideration of all available facts. To assess severity, the investigator was to use the DAIDS AE grading table for adverse events as well as any injection site reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Frequency of Treatment-Emergent Serious Adverse Events","description":"The incidence of serious adverse events (SAEs) by relationship to the study treatment. In total, there were 16 SAEs reported for eight (8) subjects (15.4%, 8/52). Thirteen of the SAEs were determined to be Unrelated, three were determined to be Unlikely Related to study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.","description":"The number of study participants who had exclusive CCR5-tropic virus at study entry and subsequently developed Dual/Mixed (D/M)- and CXCR4-tropic virus at any time during study treatment while receiving PRO 140.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Injection site haemorrhage","Diarrhoea","Arthralgia","Fatigue","Back pain"]}}}